Sugi Predict

Sugi Predict / Compounds / SCHEMBL713780

SCHEMBL713780

SCHEMBL713780

CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)C(=O)CF

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 10/20 0.56
▸ CASP7 P55210 6/20 0.52
▸ CASP1 P29466 6/20 0.52
▸ CASP9 P55211 4/20 0.52
▸ CASP4 P49662 2/20 0.49
▸ CASP6 P55212 2/20 0.49
▸ CASP8 Q14790 2/20 0.49
▸ CASP10 Q92851 2/20 0.49
▸ ELANE P08246 1/20 0.48
▸ REN P00797 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CASP5 P51878 1/20 0.47
▸ CTSL P07711 1/20 0.47
▸ CTSS P25774 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ CTSK P43235 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2033191 1.00 CASP3 (0.56) CASP3CASP7CASP1CASP9CASP4
SCHEMBL2043662 0.97 CASP3 (0.56) CASP3CASP7CASP1CASP9CASP4
SCHEMBL4952116 0.96 CASP3 (0.60) CASP3CASP7CASP1CASP9CASP4
SCHEMBL15939366 0.90 CASP3 (0.64) CASP3CASP7CASP1CASP9CASP4
SCHEMBL24213871 0.90 CASP3 (0.56) CASP3CASP7CASP1CASP9CASP6
SCHEMBL17494194 0.90 CASP3 (0.56) CASP3CASP7CASP1CASP9CASP6
SCHEMBL14646635 0.90 CASP3 (0.56) CASP3CASP7CASP1CASP9CASP6
SCHEMBL2034510 0.90 CASP1 (0.67) CASP3CASP7CASP1CASP9CASP4
SCHEMBL2043035 0.90 CASP1 (0.67) CASP3CASP7CASP1CASP9CASP4
SCHEMBL3692630 0.88 CASP3 (0.56) CASP3CASP7CASP1CASP9CASP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026044087-A1 INCREASED CELLULAR STABILITY FOR AAV PRODUCTION SHAPE THERAPEUTICS INC. (US) 2026-02-26 — — WO claimed
WO-2012154944-A9 METHODS OF TREATING AUTOPHAGY-ASSOCIATED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS STC.UNM (US) 2013-02-21 — — WO claimed
WO-2012154944-A2 METHODS OF TREATING AUTOPHAGY-ASSOCIATED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS STC.UNM (US) 2012-11-15 — — WO claimed
US-20090232866-A1 Oligopeptides as coating material for medical products HEMOTEQ AG (DE) 2009-09-17 — — US claimed
US-20030105046-A1 Interleukin converting enzyme (ICE) and central nervous system damage THE GENERAL HOSPITAL CORPORATION 2003-06-05 — — US claimed
WO-1998057664-A9 INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE YUAN JUNYING (US) 1999-04-08 — — WO claimed
EP-4709723-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
EP-4709716-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
EP-4709722-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
WO-2026044087-A1 INCREASED CELLULAR STABILITY FOR AAV PRODUCTION SHAPE THERAPEUTICS INC. (US) 2026-02-26 — — WO disclosed
EP-4430037-B1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORP (US) 2025-10-29 — — EP disclosed
WO-2025217320-A1 INHIBITORS OF RIPK3 AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2025-10-16 — — WO disclosed
US-12390467-B2 Necroptosis inducers or autophagy inhibitors or a combination thereof THE UNIVERSITY OF TOLEDO (US) 2025-08-19 — — US disclosed
US-5955593-A NUCLEOTIDE SEQUENCE CODING APOPTOSIS BINDING DOMAIN WHICH CAN FORM HETEROLOGOUS DIMERS; SCREENING SUPPRESSORS OF AGONIST; ANTISENSE AGENTS; ANTITUMOR THERAPY;DETECTION OF GENETIC DISORDERS WASHINGTON UNIVERSITY (US) 1999-09-21 — — US disclosed
WO-1998057664-A9 INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE YUAN JUNYING (US) 1999-04-08 — — WO disclosed
WO-1999003998-A1 METHODS AND COMPOSITIONS FOR TUMOR REDUCTION THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1999-01-28 — — WO disclosed
WO-1998036057-A9 THYMOCYTE CASPASE ACTIVITY AND NEGATIVE SELECTION — 1999-01-07 — — WO disclosed
WO-1998057664-A1 INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE THE GENERAL HOSPITAL CORPORATION (US) 1998-12-23 — — WO disclosed
WO-1998055863-A1 RAPID METHODS FOR IDENTIFYING MODIFIERS OF CELLULAR APOPTOSIS ACTIVITY IDUN PHARMACEUTICALS, INC. (US) 1998-12-10 — — WO disclosed
WO-1998035986-A1 RECEPTOR THAT BINDS TRAIL IMMUNEX CORPORATION (US) 1998-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12390467-B2 Necroptosis inducers or autophagy inhibitors or a combination thereof BECN1, SQSTM1, ATG7 CASP3 28/4885CASP7 36/4885CASP1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.